Skip to content

NADIMED

Active
Private limited companyfounded 200323 yrs activePrins Boudewijnlaan 7b, 2550 Kontich, BelgiumKBO/BCE: BE 0859.727.529
Summary

NADIMED has been active since 2003 and the Belgian State Gazette contains no insolvency or warning signals. The 2026 annual accounts show equity of €821,966 and a net result of €112,140. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 38% of 231 sector peers (fiscal year 2026). The computed 12-month bankruptcy probability is 0.1% (very low).

Risk analysisWatch ReportCompare
NADIMEDActiveChecked score 93/100
Risk analysis ReportCompare

Overview

Activity
Wholesale of pharmaceutical and medical goods
NACE 46460NACE 51460
1 site
Size
€13.0mturnover 2026
Staff
4.3 FTE
Equity
€821,966
Profit
€112,140
Financial health
93 Excellent Checked score 2026
Bankruptcy chance 12 m
0.1%
Structure
Parent
Mawdsley-Brooks Europe · 100%
Accounts 46 d early1 of 15 deeds read
Why 93+ Founded in 2003+ Liquidity: current ratio 1.57, cash €814,957, halved+ Size: turnover €13.0m, 4.3 FTE, total assets €2.3m+ Figures for FY 2026 (filed 15-09-2026)Show the evidence

Checked score

Score 2026
93 / 100
Excellent
Probability in this band: under 0.55%
Better than 49% of its sector peers (NACE 46, micro)
Performance against the sector, not lower risk
Every signal that weighs is under Signals.
Financial strength · tick = 2025
Strong
Solvency 61-3
equity 36.2% of total assets
Liquidity 63-6
short-term debt 61.3% · cash 35.9%
Profitability 59-16
return on assets 4.9%
Bankruptcy probability, 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%

About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.4% (26,788 companies)
Last 24 months 11-2024: < 0.1%lowest value 12-2024: < 0.1%● 0.0% vs 11-2024lowest value 01-2025: < 0.1%● 0.0% vs 12-2024lowest value 02-2025: < 0.1%● 0.0% vs 01-2025lowest value 03-2025: < 0.1%● 0.0% vs 02-2025lowest value 04-2025: < 0.1%● 0.0% vs 03-2025lowest value 05-2025: < 0.1%● 0.0% vs 04-2025lowest value 06-2025: < 0.1%● 0.0% vs 05-2025lowest value 07-2025: < 0.1%▲ +5.7% vs 06-2025 08-2025: < 0.1%▼ -2.7% vs 07-2025 09-2025: < 0.1%● 0.0% vs 08-2025 10-2025: < 0.1%▲ +11.1% vs 09-2025 11-2025: 0.1%▲ +37.5% vs 10-2025 12-2025: 0.1%● 0.0% vs 11-2025 01-2026: 0.1%● 0.0% vs 12-2025 02-2026: 0.1%● 0.0% vs 01-2026 03-2026: 0.1%● 0.0% vs 02-2026 04-2026: 0.1%● 0.0% vs 03-2026 05-2026: 0.1%▼ -3.6% vs 04-2026 06-2026: 0.1%▲ +20.8% vs 05-2026 07-2026: 0.1%▲ +10.9% vs 06-2026 08-2026: 0.1%▲ +2.8% vs 07-2026 09-2026: 0.1%▲ +13.7% vs 08-2026 10-2026: 0.1%▲ +20.5% vs 09-2026highest value
  • Founded in 2003 lowers the probability for this profile
  • Liquidity: current ratio 1.57, cash €814,957, halved lowers the probability
  • Size: turnover €13.0m, 4.3 FTE, total assets €2.3m lowers the probability for this profile
  • Figures for FY 2026 (filed 15-09-2026) lowers the probability
Credit up to €75,000 at 30 days acceptable
Liquidity ample (current ratio 1.57 against 1.61 in 2025; short-term debt: 61.3% and cash: 35.9% of total assets), but 63.8% of the assets are financed with debt.
How it is calculated

The band comes from the bankruptcy probability on a scale of 0 to 100: every 10 points more double the odds of getting through the year without bankruptcy.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Place inside the band: half the bankruptcy probability, half how the company does against its sector peers (NACE 46, micro). Better than this share of them on solvency 45%, liquidity 69%, profitability 44%, growth against the median 40%. That is performance, not lower risk; the band itself always comes from the probability.

Bankruptcy probability: model pd-v3.202610021621, computed on 03-10-2026. The model learns from Belgian bankruptcies and reads the registers, the annual accounts and the gazette.

Ceilings: negative or zero equity, a heavy loss, a special KBO legal situation and a missing filing 59 (two missing 44), an ongoing judicial reorganisation or an ending 24. Financial strength does not count in the score.

Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Five signals. The signal on the left, the evidence on the right.
−lowers risk○neutral
lowers risk · Founded in 2003
In the bankruptcy model this factor lowers the probability for this profile.
KBO
lowers risk · Liquidity: current ratio 1.57, cash €814,957, halved
In the bankruptcy model this factor lowers the probability.
NBB · annual accounts
lowers risk · Size: turnover €13.0m, 4.3 FTE, total assets €2.3m
In the bankruptcy model this factor lowers the probability for this profile.
NBB · annual accounts
lowers risk · Figures for FY 2026 (filed 15-09-2026)
In the bankruptcy model this factor lowers the probability.
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 31-03-2026 was due by 31-10-2026 and was filed on 15-09-2026, 46 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2026
46 d early
2025
23 d early
2024
37 d early
2022
28 d early
2021
19 d late
2020
37 d early
2019
36 d early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 27 days before the deadline; the sector median for financial year 2024 is 3 days before the deadline, and 39% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-03-2027 and is due by 31-10-2027. Nothing is late today. Usually files around 24 September (3 of the last 3 filed years within 30 days of that day).
Companies Code · seven months
Position in the running window
04-10-2026 today31-03-2027 close31-10-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage
  1. Annual accounts filedfiscal year 2026 · full…
  2. Weakest financial yearnet €112,140 ▼81.5%
  3. Resignation: Elinova CommV. (director)Permanent representative: Elisabeth Mattheussens ·…

Key points

  • Caution: Result fell in 2026from €607,597 to €112,140 ▼ 81.5% View
  • Positive: 8 profitable years in a rowprofit 2026: €112,140 8 years View
  • Controlled by Mawdsley-Brooks Europeknown shareholders 100% 100% View
  • Positive: Always filed on timeaccounts within the deadline every year 4 years View

By topic

Financials

Fiscal year
2026
Turnover
€13.0m
Profit
€112,140
Solvency
36.2%
Turnover▲ 7.0%
Net result
20242026
Go to Financials

Timeline

Events
16
Since
2017
Next accounts
by 31-10-2027
  1. 15-09-2026Annual accounts filed
  2. 31-03-2026Weakest financial year
  3. 23-02-2026Resignation: Elinova CommV. (director)
Go to Timeline

Company details

Sites
1
Legal form
Private limited company
Activity
Wholesale of pharmaceutical and medical goodsNACE 46460
Founded
23-07-2003
Year ends
31-03
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What other support did companies like this one receive, and it did not?Subsidies How does this company compare with its sector?Sector benchmark

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure